Targeting telomerase is an effective therapeutic strategy for treating NRAS-mutant melanoma, shows new study. Moreover, the therapeutic effect is enhanced when the strategy was paired with an inhibitor of mitochondrial function. The study from The Wistar Institute is published in Oncogene.
"Many melanoma
patients do not benefit from new treatment options or experience disease progression because of resistance. Our research advances the search for novel therapeutic strategies to treat NRAS-mutant melanoma, which is highly resistant to most therapies and associated with poor prognosis," said lead researcher Jessie Villanueva, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at Wistar.
Presurgical Targeted Therapy can Delay Recurrence of High-risk Stage 3 Melanoma
A presurgical treatment for melanoma using targeting therapies can delay the rate of relapse and progression of stage 3 metastatic melanoma.
Advertisement
‘A combination therapy that simultaneously impairs telomerase and blocks adaptive resistance mechanisms could treat NRAS-mutant melanoma.’
Tweet it Now
Targeting NRAS as well as the other oncogenes of the Ras family has proven extremely challenging, according to Villanueva, and researchers have resorted to searching for vulnerabilities in NRAS-mutant cancer cells that can provide alternative therapeutic targets.
Mutations in the regulatory element of the TERT gene, which encodes the catalytic subunit of telomerase, are found in more than 70 percent of melanomas. Telomerase is an enzyme that protects the integrity of chromosome ends during replication and represents a promising target for cancer therapy because it is absent in most normal adult cells while its reactivation in malignant cells allows continuous cell divisions.
![Melanoma Skin Cancers Linked With Reduced Risk of Alzheimer's Disease]( "Melanoma Skin Cancers Linked With Reduced Risk of Alzheimer's Disease")
Diagnosis of malignant melanoma (skin cancer) was associated with a 61% reduced risk of developing Alzheimer's disease.
"We linked the presence of mutant NRAS to TERT expression and showed that NRAS mutant melanoma cells are highly dependent on telomerase," said Villanueva. "We also demonstrated the therapeutic value of exploiting this dependency by inducing telomere dysfunction, which caused cell death selectively in NRAS mutant cells and not in normal cells that do not express telomerase."
Villanueva and colleagues studied the consequence of NRAS depletion on gene expression in NRAS-mutant melanoma cells, focusing on genes that regulate proliferation. They observed a strong decrease in expression of TERT. They then inhibited telomerase activity via TERT gene silencing or induced telomere dysfunction through a telomerase substrate, called 6-thio-dG; both interventions led to extensive cell death and DNA damage. They also observed an increase in expression of several enzymes involved in the function of mitochondria, the organelles designated to energy production, suggesting that following telomere dysfunction cells put in place an adaptive metabolic response that helps them cope with the damage.
"We asked whether inhibition of mitochondrial function could synergize with the anti-melanoma effects of telomere dysfunction," said Patricia Reyes-Uribe, a research assistant in the Villanueva Lab and the first author of the study. "We found that the mitochondrial inhibitor gamitrinib enhances the cytotoxic effects of TERT depletion or 6-thio-dG selectively in NRAS mutant tumor cells."
These observations were reproduced in vivo in a mouse model of NRAS-mutant melanoma by showing that the combination of gamitrinib and 6-thio-dG reduced tumor size and substantially prolonged survival.
"Our work provides proof-of-principle that we can successfully address drug resistance by developing combination therapies that simultaneously impair telomerase and block adaptive resistance mechanisms," added Villanueva.
Source: Eurekalert
Melanoma Skin Cancers Linked With Reduced Risk of Alzheimer's Disease
Diagnosis of malignant melanoma (skin cancer) was associated with a 61% reduced risk of developing Alzheimer's disease.
Advertisement
"We linked the presence of mutant NRAS to TERT expression and showed that NRAS mutant melanoma cells are highly dependent on telomerase," said Villanueva. "We also demonstrated the therapeutic value of exploiting this dependency by inducing telomere dysfunction, which caused cell death selectively in NRAS mutant cells and not in normal cells that do not express telomerase."
Villanueva and colleagues studied the consequence of NRAS depletion on gene expression in NRAS-mutant melanoma cells, focusing on genes that regulate proliferation. They observed a strong decrease in expression of TERT. They then inhibited telomerase activity via TERT gene silencing or induced telomere dysfunction through a telomerase substrate, called 6-thio-dG; both interventions led to extensive cell death and DNA damage. They also observed an increase in expression of several enzymes involved in the function of mitochondria, the organelles designated to energy production, suggesting that following telomere dysfunction cells put in place an adaptive metabolic response that helps them cope with the damage.
"We asked whether inhibition of mitochondrial function could synergize with the anti-melanoma effects of telomere dysfunction," said Patricia Reyes-Uribe, a research assistant in the Villanueva Lab and the first author of the study. "We found that the mitochondrial inhibitor gamitrinib enhances the cytotoxic effects of TERT depletion or 6-thio-dG selectively in NRAS mutant tumor cells."
These observations were reproduced in vivo in a mouse model of NRAS-mutant melanoma by showing that the combination of gamitrinib and 6-thio-dG reduced tumor size and substantially prolonged survival.
"Our work provides proof-of-principle that we can successfully address drug resistance by developing combination therapies that simultaneously impair telomerase and block adaptive resistance mechanisms," added Villanueva.
Source: Eurekalert
Attacking Melanoma With a Combination Therapy
Study findings have implications for treating tumors lacking tumor suppressor gene PTEN.
Advertisement
 New Treatment Could Keep Melanoma at BayChanging schedules of drug administration for melanoma can improve outcomes leading to more complete responses in animals models of the disease, revealed study. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
Women tested at high risk for breast cancer using non-clinical genetic tests overlooking family history may decide to undergo unnecessary breast surgery.
